Menu
Menu
SOPHiA GENETICS and Myriad Genetics have joined forces in a unique partnership combining Myriad’s centralized CDx and regulatory expertise with SOPHiA GENETICS’ decentralized, data-driven platform.
In this engager we explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access to precision medicine. Attendees will:
Topics:
Speakers:
Scientific innovation and the unprecedented surge in health data generated every day are transforming our understanding of disease and reshaping the future of precision medicine. As FDA-approved biomarker-targeted therapies continue to expand rapidly, BioPharma companies face increasing pressure to bring them to the market faster to the patients who need them the most. As such, the delivery of robust, accurate, and scalable end-to-end diagnostic solutions across the globe has become essential.
In this talk, we will explore how SOPHiA GENETICS empowers BioPharma to advance precision medicine by harnessing AI-powered analytics and next-generation genomics solutions, improving access to new therapies worldwide and helping close critical health equity gaps.
Speaker:
Jess Lambe, MBA
VP & Managing Director BioPharma Business Development, SOPHiA GENETICS
SOPHiA GENETICS is heading to the European Society for Medical Oncology Congress (ESMO) 2026 in Madrid, Spain. Meet our team at Booth #8068 to learn how we are helping advance precision medicine through intelligent analytics and collaborative innovation.
More updates on our participation and activities will be announced soon!
SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. Find us at Booth #13 where our team of experts will be ready to discuss how SOPHiA DDM™ platform is helping laboratories and healthcare institutions advance data-driven oncology insights.
Come explore our partnership with the Memorial Sloan Kettering Cancer Center and our latest updates across the MSK solutions portfolio, including enhanced CNV detection with tumor purity and ploidy analysis in MSK-IMPACT® Flex, and new capabilities in MSK-ACCESS® including MSI and ctDNA fraction, now available on GEN2.
Also learn more about OncoKB™ which is now fully embedded in SOPHiA DDM™ oncology workflows, and what that means for somatic variant interpretation in practice.
Industry Symposium
Join our Industry Symposium to explore how combining MSK-IMPACT® Flex and MSK-ACCESS® on the SOPHiA DDM™ Platform unlocks deeper, more complete oncology insights. From real-world use cases to the latest liquid biopsy enhancements, this is a must-attend session for those looking to take their genomic profiling further.
Monday, 15 June | 2:30pm – 3:30pm | Ballroom
Integrating tissue and liquid biopsy for in-depth precision oncology insights
Dr. Maria De Bonis, Biologist and Health Manager, Fondazione Policlinico A. Gemelli IRCCS, Italy
Lina Li, Product Director of Solid Tumors, SOPHiA GENETICS
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.
Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don't miss this unique opportunity and reserve your spot now!
MTAP deletion is rapidly emerging as a clinically actionable biomarker across multiple tumor types, frequently associated with a poor prognosis. While this is driving new therapeutic opportunities, it also exposes a major challenge for precision oncology trials: accurately testing for difficult and novel biomarkers. In Europe, especially, this gap continues to delay clinical trial enrolment and slow therapeutic progress.
In this webinar, we will explore how SOPHiA GENETICS, in partnership with ARC Regulatory, is addressing these challenges by implementing a comprehensive genomic profiling assay to enable biomarker identification and patient enrolment for clinical trials across Europe. By combining SOPHiA GENETICS’ AI-powered technology with ARC Regulatory’s expertise in assay implementation and workflow validation, we accelerate CTA development in instances such as MTAP deletion. Together, we aim to reduce regulatory risk in clinical research programs, shorten timelines for clinical trial recruitment, and broaden clinical trial recruitment in Europe.
Join us to gain insights into the nuances of European clinical trial testing and how robust genomic solutions can advance precision oncology research and ultimately improve patient outcomes.
Speakers:
The future of precision medicine is coming to San Sebastián!
The EMEA Innovation Summit by SOPHiA GENETICS explores how precision medicine is scaling today, and what breakthroughs will shape clinical care tomorrow.
Following the success of our 2025 edition in Rolle, we’re thrilled to host the next SOPHiA GENETICS Innovation Summit at the iconic Real Sociedad Arena, a venue that captures the energy, innovation, and collaboration that define our community.
This year’s agenda is set to dive deep into innovation, from AI-driven discovery and liquid biopsy advancements to collaborative approaches in oncology and clinical genomics. Expect thought-provoking sessions, impactful discussions, and cross-industry networking designed to accelerate innovation in healthcare.
Over two days, the event brings together:
Together, we connect insights with real-world impact bridging today’s scalable platforms with tomorrow’s clinical breakthroughs.
The day will begin with a focus on scalability and operational maturity, tackling the growing challenges of data volume and complexity while building robust end-to-end workflows. Through AI-driven insights, we’ll explore how to accelerate the global adoption of precision medicine. In the afternoon, the spotlight shifts to future-facing clinical innovation, diving into next-generation data modalities and their applications across solid tumors, liquid biopsy, blood cancers, and germline analysis. Bringing it all together, the sessions highlight real-world clinical studies, emerging technologies, and pharma perspectives, showcasing how advanced analytics are translating into meaningful clinical impact.
Fill out the form to secure your spot!
Do you have any questions or require further assistance? Please get in touch with us!
We are glad to return to Swiss Biotech Day 2026, where you will have the chance to meet our leadership team for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine
The SOPHiA GENETICS team is thrilled to see you at our Fireside chat on Monday, May 4th from 15.30 to 16.15, in Room Delhi – Level 0.
“Liquid Biopsy at a Tipping Point in Precision Oncology”
Join Philippe Menu, MD, PhD, MBA, EVP, Chief Medical & Product Officer, SOPHiA GENETICS, Elena Guerini Rocco, MD, Director of the Oncology Genetics Unit, IEO – Istituto Europeo di Oncologia, and Thomas di Maio, EU/Canada Diagnostic Lead, AstraZeneca for an insightful conversation about the liquid biopsy movement.
SOPHiA GENETICS is thrilled to be back at ASCO 2026! Meet our experts at booth #11111 to learn hear about our BioPharma solutions. Learn how to leverage our unique AI-powered data analytics and genomics expertise to accelerate late-stage clinical development programs. From diagnostic testing development & deployment, to insights and multimodal RWE, we are the right partner for pharma, enabling the advancement and commercialization of better precision therapies.
If you are attending this ASCO 2026 Annual Meeting, don’t miss our Poster presentation on Sunday, May 31st, from 9.00 am to 12.00 pm.
Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.
Loïc Ferrer, Senior Manager Multimodal R&D, SOPHiA GENETICS
We are thrilled to be at the inaugural World Clinical Biomarkers & Companion Diagnostics Summit Japan. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
The SOPHiA GENETICS team is thrilled to see you join our Plenary Talk.
Plenary talk on Tuesday, May 19th from 12.50 to 1.20 pm.
“Liquid Biopsy in Japan: From Global Vision to Local Reality”
Philippe Menu, MD, PhD, MBA, EVP, Chief Medical & Product Officer, SOPHiA GENETICS
Michel Mommejat, President/Representative Director and Chief Innovation Officer, A.D.A.M. Innovations
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.